Band Therapeutics

Band Therapeutics, LLC

...

Wholly-owned subsidiary of Guardian Therapeutics.

...

Inventor and development sponsor of BT200, a VWF binding aptamer in clinical development for treatment of hereditary bleeding disorders.

...

Specialized in application of aptamer therapeutic technology to diseases related to Von Willebrand Factor.

BT200


...
...

Zhu et al, J Thromb Haemost. 2020 Feb 3.

BT200 is a PEGylated aptamer that binds A1 domain of human VWF.

  • BT200 has a cognate aptamer reversal agent (BT101) with in vivo proof of mechanism in non-human primates.

Selected Publications:

BT200 Phase 1 program (NCT04103034) was completed in 4Q20.

  • 112 healthy volunteers in SAD, MAD, relative bioavailability, and pharmacologic challenge studies.
  • Overall safety & tolerability profile is excellent.
  • PK profile compatible with once weekly, small volume subcutaneous dosing regimen.
  • Headline Clinical Proof of Mechanism results presented at European Hematology Association Congress 2021.
    • BT200 Phase 1 clinical proof of mechanism oral presentation at European Hematology Association Virtual Congress, June 9 - 17, 2021
      Title: "HALF-LIFE PROLONGATION OF VON WILLEBRAND FACTOR: A NEW THERAPEUTIC STRATEGY FOR HAEMOPHILIA A AND VON WILLEBRAND DISEASE"
      Session Title: Dilemmas in coagulation and thrombosis
      Final Abstract Code: S302
      Narrated slide presentation video link

BT200 Phase 2 pilot study in hereditary bleeding disorders (NCT04677803) initiated in 1Q21.

  • “Basket design” trial includes patients with either Von Willebrand Disease or Hemophilia A.
  • Headline clinical proof of concept results presented at ISTH meeting in July 2021.
    • BT200 Phase 2 clinical proof of concept in Von Willebrand Disease Type 2b oral presentation at International Society for Thrombosis and Haemostasis Virtual Congress, July 17-21, 2021
      Title: BT200 increases von Willebrand factor (VWF), FVIII and platelet counts in patients with von Willebrand disease (VWD) type IIb
      Abstract Number: OC 72.1
      Session Date: 2021-07-21
      Session Time: 13:00 - 14:00 U.S. Eastern Daylight Time
    • BT200 Phase 2 clinical proof of concept in hemophilia A late-breaking clinical trial presentation at International Society for Thrombosis and Haemostasis Virtual Congress, July 17-21, 2021
      Abstract Title: The VWF-A1 domain binding aptamer BT200 prolongs the half-lives of different factor VIII (FVIII) products in patients with severe hemophilia A and increases FVIII levels in non-severe hemophilia A.
      Abstract Presentation Number: LB 02.1
      Session Title: Late-breaking Abstract Session II
      Session Date: Wednesday, July 21, 2021
      Session Time: 10:00:00 AM - 11:00:00 AM U.S. Eastern Daylight Time

BR200 increases von Willebrand factor (VWF), Factor VIII and platelet counts in patients with von Willebrand disease (VWD) type IIb



The VWF-A1 domain binding aptamer BT200 prolongs the half-lives of different factor VIII (FVIII) products in patients with severe hemophilia A and increases FVIII levels in non-severe hemophilia



EHA2021 - HALF-LIFE PROLONGATION OF VON WILLEBRAND FACTOR:
A new therapeutic strategy for haemophilia A and von Willebrand Disease

Katarina Kovacevic, PhD, Department of Clinical Pharmacology, Medical University of Vienna, 11.06.2021.

Contact

© 2021 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com